Cargando…

Guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native Danes with type 2 diabetes: Population-wide analyses

The prevalence of type 2 diabetes (T2D) is higher in migrants compared to native populations in many countries, but the evidence on disparities in T2D care in migrants is inconsistent. Therefore, this study aimed to examine this in Denmark. In a cross-sectional, register-based study on 254,097 indiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Isaksen, Anders Aasted, Sandbæk, Annelli, Skriver, Mette Vinther, Andersen, Gregers Stig, Bjerg, Lasse
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584163/
https://www.ncbi.nlm.nih.gov/pubmed/37851595
http://dx.doi.org/10.1371/journal.pgph.0001277
_version_ 1785122694499401728
author Isaksen, Anders Aasted
Sandbæk, Annelli
Skriver, Mette Vinther
Andersen, Gregers Stig
Bjerg, Lasse
author_facet Isaksen, Anders Aasted
Sandbæk, Annelli
Skriver, Mette Vinther
Andersen, Gregers Stig
Bjerg, Lasse
author_sort Isaksen, Anders Aasted
collection PubMed
description The prevalence of type 2 diabetes (T2D) is higher in migrants compared to native populations in many countries, but the evidence on disparities in T2D care in migrants is inconsistent. Therefore, this study aimed to examine this in Denmark. In a cross-sectional, register-based study on 254,097 individuals with T2D, 11 indicators of guideline-level care were analysed: a) monitoring: hemoglobin-A1c (HbA1c), low-density lipoprotein cholesterol (LDL-C), screening for diabetic nephropathy, retinopathy, and foot disease, b) biomarker control: HbA1c and LDL-C levels, and c) pharmacological treatment: glucose-lowering drugs (GLD), lipid-lowering drugs, angiotensin-converting enzyme-inhibitors/angiotensin receptor blockers, and antiplatelet therapy. Migrants were grouped by countries of origin: Middle East, Europe, Turkey, Former Yugoslavia, Pakistan, Sri Lanka, Somalia, Vietnam. In all migrant groups except the Europe-group, T2D was more prevalent than in native Danes (crude relative risk (RR) from 0.62 [0.61–0.64] (Europe) to 3.98 [3.82–4.14] (Sri Lanka)). In eight indicators, non-fulfillment was common (>25% among native Danes). Apart from monitoring in the Sri Lanka-group, migrants were at similar or higher risk of non-fulfillment than native Danes across all indicators of monitoring and biomarker control (RR from 0.64 [0.51–0.80] (HbA1c monitoring, Sri Lanka) to 1.78 [1.67–1.90] (LDL-C control, Somalia)), while no overall pattern was observed for pharmacological treatment (RR from 0.61 [0.46–0.80] (GLD, Sri Lanka) to 1.67 [1.34–2.09] (GLD, Somalia)). Care was poorest in migrants from Somalia, who had increased risk in all eleven indicators, and the highest risk in nine. Adjusted risks were elevated in some migrant groups, particularly in indicators of biomarker control (fully-adjusted RR from 0.84 [0.75–0.94] (LDL-C levels, Vietnam) to 1.44 [1.35–1.54] (LDL-C levels, Somalia)). In most migrant groups, T2D was more prevalent, and monitoring and biomarker control was inferior compared to native Danes. Migrants from Somalia received the poorest care overall, and had exceedingly high lipid levels.
format Online
Article
Text
id pubmed-10584163
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-105841632023-10-19 Guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native Danes with type 2 diabetes: Population-wide analyses Isaksen, Anders Aasted Sandbæk, Annelli Skriver, Mette Vinther Andersen, Gregers Stig Bjerg, Lasse PLOS Glob Public Health Research Article The prevalence of type 2 diabetes (T2D) is higher in migrants compared to native populations in many countries, but the evidence on disparities in T2D care in migrants is inconsistent. Therefore, this study aimed to examine this in Denmark. In a cross-sectional, register-based study on 254,097 individuals with T2D, 11 indicators of guideline-level care were analysed: a) monitoring: hemoglobin-A1c (HbA1c), low-density lipoprotein cholesterol (LDL-C), screening for diabetic nephropathy, retinopathy, and foot disease, b) biomarker control: HbA1c and LDL-C levels, and c) pharmacological treatment: glucose-lowering drugs (GLD), lipid-lowering drugs, angiotensin-converting enzyme-inhibitors/angiotensin receptor blockers, and antiplatelet therapy. Migrants were grouped by countries of origin: Middle East, Europe, Turkey, Former Yugoslavia, Pakistan, Sri Lanka, Somalia, Vietnam. In all migrant groups except the Europe-group, T2D was more prevalent than in native Danes (crude relative risk (RR) from 0.62 [0.61–0.64] (Europe) to 3.98 [3.82–4.14] (Sri Lanka)). In eight indicators, non-fulfillment was common (>25% among native Danes). Apart from monitoring in the Sri Lanka-group, migrants were at similar or higher risk of non-fulfillment than native Danes across all indicators of monitoring and biomarker control (RR from 0.64 [0.51–0.80] (HbA1c monitoring, Sri Lanka) to 1.78 [1.67–1.90] (LDL-C control, Somalia)), while no overall pattern was observed for pharmacological treatment (RR from 0.61 [0.46–0.80] (GLD, Sri Lanka) to 1.67 [1.34–2.09] (GLD, Somalia)). Care was poorest in migrants from Somalia, who had increased risk in all eleven indicators, and the highest risk in nine. Adjusted risks were elevated in some migrant groups, particularly in indicators of biomarker control (fully-adjusted RR from 0.84 [0.75–0.94] (LDL-C levels, Vietnam) to 1.44 [1.35–1.54] (LDL-C levels, Somalia)). In most migrant groups, T2D was more prevalent, and monitoring and biomarker control was inferior compared to native Danes. Migrants from Somalia received the poorest care overall, and had exceedingly high lipid levels. Public Library of Science 2023-10-18 /pmc/articles/PMC10584163/ /pubmed/37851595 http://dx.doi.org/10.1371/journal.pgph.0001277 Text en © 2023 Isaksen et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Isaksen, Anders Aasted
Sandbæk, Annelli
Skriver, Mette Vinther
Andersen, Gregers Stig
Bjerg, Lasse
Guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native Danes with type 2 diabetes: Population-wide analyses
title Guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native Danes with type 2 diabetes: Population-wide analyses
title_full Guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native Danes with type 2 diabetes: Population-wide analyses
title_fullStr Guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native Danes with type 2 diabetes: Population-wide analyses
title_full_unstemmed Guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native Danes with type 2 diabetes: Population-wide analyses
title_short Guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native Danes with type 2 diabetes: Population-wide analyses
title_sort guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native danes with type 2 diabetes: population-wide analyses
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584163/
https://www.ncbi.nlm.nih.gov/pubmed/37851595
http://dx.doi.org/10.1371/journal.pgph.0001277
work_keys_str_mv AT isaksenandersaasted guidelinelevelmonitoringbiomarkerlevelsandpharmacologicaltreatmentinmigrantsandnativedaneswithtype2diabetespopulationwideanalyses
AT sandbækannelli guidelinelevelmonitoringbiomarkerlevelsandpharmacologicaltreatmentinmigrantsandnativedaneswithtype2diabetespopulationwideanalyses
AT skrivermettevinther guidelinelevelmonitoringbiomarkerlevelsandpharmacologicaltreatmentinmigrantsandnativedaneswithtype2diabetespopulationwideanalyses
AT andersengregersstig guidelinelevelmonitoringbiomarkerlevelsandpharmacologicaltreatmentinmigrantsandnativedaneswithtype2diabetespopulationwideanalyses
AT bjerglasse guidelinelevelmonitoringbiomarkerlevelsandpharmacologicaltreatmentinmigrantsandnativedaneswithtype2diabetespopulationwideanalyses